metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
endometrial cancer endometrial cancer
versus placebo plus SoC
	dostarlimab plus soC
	RUBY (part 2), 2024 NCT03981796	RCT	endometrial cancer	dostarlimab (500 mg) followed by dostarlimab plus niraparib	placebo	primary advanced stage III or IV or first recurrent endometrial cancer	-/-	low	suggested	suggested 40 % decrease in progression or deaths (PFS) (PE) The PFS improvement with dostarlimab was observed in the overall patient population and in a subset of patients with mismatch repair–proficient (MMRp) or microsatellite stable (MSS) tumors, meeting the primary end point of the study. Data pertaining to overall survival (OS), a key secondary end point, are immature but will continue to be followed.
	RUBY (part 1), 2023 NCT03981796	RCT	endometrial cancer	dostarlimab (500 mg)	placebo	primary advanced stage III or IV or first recurrent endometrial cancer	245 / 249	low	conclusif	demonstrated 31 % decrease in deaths (OS) (PE) suggested 36 % decrease in progression or deaths (PFS) (PE)